The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells

• DOI: 10.1097/gme.0b013e31820e5ac5
• Publication Date: 2011-04-29T08:45:19Z
• Authors: Hans Neubauer; Yang Yang; Harald Seeger; Tanja Fehm; Michael A. Cahill; Xiaowen Tong; Xiangyan Ruan; Alfred O. Mueck
• Keywords: Dose-Response Relationship, Drug; Estradiol; Membrane Proteins; Breast Neoplasms; Medroxyprogesterone Acetate; 3. Good health; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; Contraceptive Agents, Female; Humans; Female; Receptors, Progesterone; Fulvestrant; Cell Division; Cell Proliferation

Breast cancer risk is still an important topic regarding hormone therapy as well as oral contraception. Evidence that progestogens may play a crucial role is accumulating. Progesterone receptor membrane component 1 (PGRMC1) expressed in breast cancer may be important in tumorigenesis and thus may increase breast cancer risk. The aim of this project was to investigate the influence of different estradiol (E2) concentrations and the addition of two progestogens on MCF-7 breast cancer cells overexpressing PGRMC1.MCF-7 cells were stably transfected with PGRMC1 expression plasmid (MCF-7/PGRMC1-3HA [WT-12]). To test the effects of E2 and progestogens on cell proliferation, MCF-7 and WT-12 cells were stimulated with different concentrations of E2 (10 and 10 M) alone and in combination with progesterone and medroxyprogesterone acetate (each 10 M).E2 elicited a concentration-dependent proliferative effect on both cell lines, which was much more pronounced in WT-12 cells (50% vs 200%). This effect could be completely abrogated by the addition of the E2 antagonist fulvestrant. Addition of progesterone had no influence on the E2-induced effect, whereas medroxy-progesterone acetate enhanced the E2-induced effect at a low E2 concentration, which was, again, more pronounced in the WT-12 cells. The figures were between 20% and 40% in MCF-7 and between 60% and 250% in WT-12 cells.Overexpression of PGRMC1 sensitizes the proliferative response of the MCF-7 breast cancer cell line to estradiol. The effect of progestogens on breast cancer tumorigenesis may depend on the specific progestogen used for hormone therapy or oral contraception.